endpts.com·Jun 12, 2026
Sciwind Biosciences has partnered with Pfizer and Verdiva Bio to license its obesity drug, ecnoglutide, but is seeking additional partnerships to expand its reach.
The key insight for you is that Sciwind Biosciences, despite already having licensed its GLP-1 obesity drug to Pfizer and Verdina Bio, is actively seeking additional Western partners. This indicates potential opportunities for investment or collaboration in the obesity drug market, particularly around GLP-1 therapeutics, where partnerships are being actively pursued.